Related Experiment Video
Updated: May 20, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
From immunomodulators (IMiDs) to cereblon E3 ligase modulator (CELMoDs): the evolution of cereblon modulators in
Aditi Saha1, Khushali Jhaveri2, Guilherme F Perini3
1Department of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Abstract:
Cereblon E3 ligase modulating drugs (CELMoDs) are next-generation immunomodulators (IMiDs) with a promising efficacy and safety profile. Early-phase clinical trials have shown clinical activity in heavily pretreated lymphomas, including those refractory to prior IMiD therapy or to cellular immunotherapies such as CAR-T. CELMoDs show potential as a fixed-duration, chemo-free option with durable responses in both relapsed/refractory (R/R) and treatment-naïve B-NHL. This review offers an exploration of cereblon (CRBN) as key for lymphomagenesis and highlights the mechanisms by which IMiDs and CELMoD target CRBN. Additionally, we discussed the key findings from early-phase clinical trials evaluating these newer agents as monotherapy and in combination regimens across first-line and R/R settings. Finally, we focused on ongoing clinical trials and discussed how CELMoDs may reshape the current treatment landscape and potentially redefine the standard of care in B-cell lymphomas.
Related Concept Videos
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Immunoglobulin-like Cell Adhesion Molecules
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

